Mycovia Pharmaceuticals

Mycovia Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for women's health and dermatology, particularly in the area of fungal infections. The company specializes in treating recurrent vulvovaginal candidiasis (RVVC), a common yeast infection that significantly affects women's physical and psychological well-being. Mycovia's lead product, VT-1161, is an oral antifungal therapy designed to address a range of fungal infections. Additionally, the company is advancing VT-1598 and its analogues, which are currently in preclinical development for both oral and intravenous treatments targeting invasive fungal infections. Founded in 2011 and headquartered in Durham, North Carolina, Mycovia Pharmaceuticals is committed to addressing unmet medical needs in women's health.